3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Observational
2
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Conditions
Neoplasms
2
Urinary Bladder Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Urine Specimen Collection
×
Clear all
NCT02807129
2026-01-21
AgElOn
CHU de Reims
Phase NA
Completed
296 enrolled
NCT05151341
2025-07-24
URODX-FGFR3
Institut de Cancérologie de Lorraine
Phase NA
Completed
190 enrolled